Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2011

View Archived Issues

Phase I study assesses AstraZeneca chemokine CXCR2 receptor antagonist in healthy volunteers

Millennium Pharmaceuticals discloses updated results from ongoing phase I trial of MLN-9708

Novel chitosan-based antibacterial agent developed at Synedgen

Lundbeck synthesizes multiple metabotropic glutamate receptor modulators

BTG provides 6-month update

New biomarker panel predicts risk of adverse events in patients with chronic heart failure

Bavarian Nordic gains rights to NCI anticancer vaccine candidate

Shionogi presents new oxazolidinones with potent antibacterial activity in vitro and in vivo

Pharmalucia discloses new photosensitizing agents

Novel prostanoid DP1 receptor antagonist patented by Sanofi

X-BODY BioSciences partners with Tanabe Research Laboratories for antibody therapeutics

Lightlake announces plans for phase II trials of bulimia nervosa therapy

New PLK1 inhibitors developed

Pfizer licenses neratinib to Puma Biotechnology

Alexza Pharmaceuticals partners with Grupo Ferrer for Adasuve

New cross-linked multimeric proteins for Fabry's disease claimed by Protalix Biotherapeutics

Servier exercises option to acquire sole rights to high-impact Ampakine product

Biovest presents regulatory strategy for BiovaxID in follicular lymphoma

Theratechnologies discovers novel GRF peptide

Probiodrug reports novel glutaminyl-peptide cyclotransferase inhibitors

Enrollment complete in Peregrine phase II NSCLC trial

BioCancell recruits first patients in BC-819 pancreatic cancer study

Dynavax reports more data from phase III Heplisav study

Millennium withdraws sNDA for Velcade

FDA approves Lilly's Cialis for new indications

Metabolic Solutions Development receives NIH grant for MSDC-0602 program

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...